FGF9 and metabolic dysfunction-associated steatohepatitis: Our findings highlighted the potential pharmacological targeting of FGF9, particularly for its fibrosis‐promoting effect, as a promising clinical strategy to treat NASH at an early stage and thereby prevent NASH‐driven HCC formation.